Juvisync is made by MSD International GmbH for Merck & Co., Inc.
Juvisync is a combination of sitagliptin and simvastatin.
Sitagliptin belongs to a class of
diabetes medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones.
As a DPP-4 inhibitor, sitagliptin slows down the breakdown of incretin hormones, increasing the level of these hormones in the body. It is this increase in incretin hormones that is responsible for the beneficial actions of sitagliptin, such as increasing
insulin production in response to meals and decreasing the amount of glucose (sugar) that the liver produces.
Because incretin hormones are more active in response to higher blood sugar levels (and are less active in response to low blood sugar), the risk of dangerously low blood sugar (hypoglycemia) is low with sitagliptin.
Simvastatin is part of a class of drugs called statins. It works by blocking a particular enzyme (HMG-CoA reductase) that controls the rate of
cholesterol production in the body. This causes the liver to make less cholesterol. It also increases the liver's ability to collect and get rid of
LDL cholesterol.
HealthSavvy Sign In
|
